gvtcx

Support of existing Low Density Lipid (LDL) Removal Apheresis Systems

NHS Blood and Transplant Published 18 Feb 2026 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£100,000
Statuscomplete
Category (CPV) 50420000
Deadline31 Aug 2025
Contract start20 Jan 2026
Contract end19 Jan 2028
Procedureselective
SME suitableNo
OCIDocds-b5fd17-d70af731-d753-40ab-87b9-bea99abb9331

Award

SupplierValueDateStatus
Fresenius Medical Care (UK) Limited £337,798 20 Jan 2026 active

description

NHS Blood and Transplant (NHBST) is a Special Health Authority within the NHS and is responsible for the provision of blood components and a range of associated laboratory and patient therapeutic services to hospitals in England and Wales.

Therapeutic Apheresis Services (TAS) provide lifesaving and life-enhancing therapies to adults and children from across a range of clinical specialties. Patients receive treatment either at their hospital bedside or where clinically appropriate as an outpatient in an NHS Blood and Transplant (NHSBT) unit. NHSBT provides regional access to apheresis services from 11 dedicated units across England and Wales.

Requirement for support of existing Low Density Lipid (LDL) Removal Apheresis Systems.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
18 Feb 2026 Award (award) · 603215cd-b4a4-4372-9470-041aab34ce01-884571

more from NHS Blood and Transplant

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.